Moffitt Presentations at SITC 2023
Note - all times are listed as PST
-
Thursday, November 2, 2023
Time Location Type Title Author/Presentor 12:15 p.m. Exhibit Hall D Oral (1427) Evaluating MHC-II antigen presentation in vivo to identify targets for immunotherapy Alex Jaeger, PhD -
Friday, November 3, 2023
Time
Location
Type
Title
Author/Presenter
10:35 a.m. Exhibit Hall C Oral (62) Pathological, transcriptomic and prognostic assessment of lymphoid aggregates in patients with primary and metastatic melanoma
Lilit Karapeytan, MD 3:20-4:45 p.m. Ballroom 6AB Session Co-Chair Session 207c: SITC Surgery Committee Session
Vernon Sondak, MD 12:15-1:45 p.m. and 5:30-7 p.m. Exhibit Halls A & B1 Poster (45) An Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits for High-Risk Melanoma Ahmad Tarhini, MD, PhD 12:15-1:45 p.m. and 5:30-7 p.m. Exhibit Halls A & B1 Poster
(187) Immune Checkpoint Inhibitor (CPI) Efficacy in Gastrointestinal Tumors with Microsatellite-stable with High Tumor Mutational Burden (MSS-TMB-H) Compared to Microsatellite instability-high (MSI-H) James Yu 12:15-1:45 p.m. and 5:30-7 p.m. Exhibit Halls A & B1 Poster (151) Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines Timothy Shaw, PhD 12:15-1:45 p.m. and 5:30-7 p.m. Exhibit Halls A & B1 Poster (345) Targeting acidity in bladder cancer to enhance efficacy of adoptive cell therapy (ACT) with tumor reactive T cells Sarah Bazargan 12:15-1:45 p.m. and 5:30-7 p.m. Exhibit Halls A & B1 Poster (625) Immune priming IFx-Hu2.0 promotes antibody responses necessary for anti-PD1 responses in PD-1 refractory melanoma patients Joseph Markowitz, MD, PhD 12:15-1:45 p.m. and 5:30-7 p.m. Exhibit Halls A & B1 Poster (351) Expansion of T cells from the Cerebrospinal Fluid of Melanoma Patients with Leptomeningeal Disease Michael Carter 12:15-1:45 p.m. and 5:30-7 p.m. Exhibit Halls A & B1 Poster (185) Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors Xuefeng Wang, PhD 12:15-1:45 p.m. and 5:30-7 p.m. Exhibit Halls A & B1 Poster (1509-B) STING signaling-intact tumors display a 12-chemokine gene signature associated with tertiary lymphoid structures and favorable prognosis Rana Falahat -
Saturday, November 4, 2023
Time Location Type Title Author/Presenter 11:55 a.m. - 1:25 p.m. and 7 - 8 p.m. Exhibit Halls A & B1 Poster (674) A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients. Christine Chung, MD 11:55 a.m. - 1:25 p.m. and 7 - 8 p.m. Exhibit Halls A & B1 Poster (346) Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal (CRC) and GI cancers. Matthew Beatty 11:55 a.m. - 1:25 p.m. and 7 - 8 p.m. Exhibit Halls A & B1 Poster (380) Exploring the Microenvironment of Clear Cell Renal Cell Carcinoma to Improve Therapy with Tumor Infiltrating Lymphocytes Marine Potez